menu
    • menu
    [{"orgOrder":0,"company":"Klotho Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"KLTO-202","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Klotho Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Klotho Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Klotho Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Klotho Neurosciences","sponsor":"Aavnergene","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"KLTO-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Klotho Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Klotho Neurosciences \/ Aavnergene","highestDevelopmentStatusID":"4","companyTruncated":"Klotho Neurosciences \/ Aavnergene"}]

    Find Clinical Drug Pipeline Developments & Deals by Klotho Neurosciences

    Menu

    Klotho Neurosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Klotho Neurosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Klotho Neurosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KLTO-101

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Aavnergene

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Klotho Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

                            Details : The parternship aims to advance the clinical development of Klotho's KLTO-101 gene therapy product, which is being evaluated for Alzheimer Disease.

                            Product Name : KLTO-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 22, 2025

                            Lead Product(s) : KLTO-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Aavnergene

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Klotho Neurosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Klotho Neurosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KLTO-202

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Klotho Progresses Manufacturing Gene Therapy for ALS Treatment

                            Details : KLTO-202, its investigational gene therapy, which is being evaluated for the treatment of amyotrophic lateral sclerosis (ALS).

                            Product Name : KLTO-202

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            June 30, 2025

                            Lead Product(s) : KLTO-202

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth